310 related articles for article (PubMed ID: 32229193)
1. Evaluation of the anti-cervical cancer effect of a prodrug ：CBZ-AAN-DOX with hypoxic cell culture and tumor-bearing zebrafish models.
Chen HC; Rui W; You SY; Liu XW; Huang J; Chen HY
Exp Cell Res; 2020 Jun; 391(1):111980. PubMed ID: 32229193
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells Under Hypoxic Conditions.
Chen H; Liu X; Clayman ES; Shao F; Xiao M; Tian X; Fu W; Zhang C; Ruan B; Zhou P; Liu Z; Wang Y; Rui W
Chem Biol Drug Des; 2015 Oct; 86(4):589-98. PubMed ID: 25619622
[TBL] [Abstract][Full Text] [Related]
3. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
4. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
[TBL] [Abstract][Full Text] [Related]
5. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
[TBL] [Abstract][Full Text] [Related]
6. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
7. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
8. Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis.
Lin Y; Wei C; Liu Y; Qiu Y; Liu C; Guo F
Cancer Sci; 2013 Sep; 104(9):1217-25. PubMed ID: 23691974
[TBL] [Abstract][Full Text] [Related]
9. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
10. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.
Zhang M; Jiang Z; Chen S; Wu Z; Chen K; Wu Y
Chem Biol Drug Des; 2018 Feb; 91(2):534-544. PubMed ID: 28994241
[TBL] [Abstract][Full Text] [Related]
11. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
[TBL] [Abstract][Full Text] [Related]
13. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
14. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
[TBL] [Abstract][Full Text] [Related]
15. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
16. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling.
Chen YJ; Cheng YJ; Hung AC; Wu YC; Hou MF; Tyan YC; Yuan SS
Gynecol Oncol; 2013 Dec; 131(3):734-43. PubMed ID: 24145114
[TBL] [Abstract][Full Text] [Related]
17. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
[TBL] [Abstract][Full Text] [Related]
18. Thiourea Modified Doxorubicin: A Perspective pH-Sensitive Prodrug.
Krasnovskaya OO; Malinnikov VM; Dashkova NS; Gerasimov VM; Grishina IV; Kireev II; Lavrushkina SV; Panchenko PA; Zakharko MA; Ignatov PA; Fedorova OA; Jonusauskas G; Skvortsov DA; Kovalev SS; Beloglazkina EK; Zyk NV; Majouga AG
Bioconjug Chem; 2019 Mar; 30(3):741-750. PubMed ID: 30726065
[TBL] [Abstract][Full Text] [Related]
19. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model.
Li D; Qin Q; Wang XY; Shi HS; Luo M; Guo FC; Wang W; Wang YS
Oncol Rep; 2014 Mar; 31(3):1287-95. PubMed ID: 24378474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
